Thank you, Mr. Malo.
We can drop clause 6, clause 7, clause 8, clause 11, clause 12, and clause 14. They deal with several issues that committee members have raised as concerns with the bill. That would provide a compromise, so that the process of acquiring and distributing the generic drugs would be changed because of situations like the one in Rwanda, for example, and others that never took place.
But the structures and some of the features would still be in place, addressing issues related to everything from diversions, the way drugs are shipped, and the processes in that. That's one of the reasons why we have backed off f some of the changes, even to the schedules, because the heart of the bill is changing the process through which a country can procure a generic drug through CAMR and how it can distribute a drug through CAMR, and, in this particular case, the volumes. This would provide a greater ability for that country and the NGOs to be able to apply CAMR in their respective countries.
The other issues, although important, are not nearly as important as this particular issue. So in the interests of time and compromise, we can't compromise on this one, but on other ones we can, to make the bill a little more efficient.